Monthly Archives: March 2017

Diabetes: Heart attack risk due to loss of small blood vessels around the heart – Medical News Today

Posted: March 24, 2017 at 3:41 pm

People with diabetes have a significantly higher risk for heart attack. Now, new research suggests that diabetes damages the small blood vessels around the heart, and this might explain the link to heart attack. In a study reported in the Journal of the American College of Cardiology, the researchers also propose a solution may lie in gene therapy.

Diabetes is a chronic disease that arises either because the body does not produce enough insulin (typical of type 1 diabetes) or because it cannot effectively use the insulin it produces (typical of type 2 diabetes). Around 90 percent of people with diabetes have type 2.

Insulin is a hormone that helps keep blood sugar (glucose) under control. Uncontrolled diabetes results in high blood sugar, or hyperglycemia, which, over time, damages many parts of the body, including nerves and blood vessels.

The number of people with diabetes worldwide was estimated to be 422 million in 2014, up from 108 million in 1980. The disease is a major cause of blindness, heart attack, stroke, kidney failure, and lower limb amputation

In the United States, there are now more than 29 million people with diabetes, up from 26 million in 2010.

Another 86 million people have prediabetes, a condition in which blood sugar is higher than normal but not yet in the range for type 2 diabetes.

Fast facts about diabetes

Learn more about diabetes

The new study - led by researchers at Technical University of Munich (TUM) in Germany - investigates the effect of diabetes on the small blood vessels, or capillaries, that surround the heart. Damage to these can affect the whole of the heart muscle.

The heart's network of veins and arteries and small offshoots into capillaries can be compared to a road traffic network. If one small minor road is blocked, it has little effect on the whole network.

However, if more and more small side roads come to a halt, the traffic on the main roads and highways becomes denser and denser, and eventually the whole system seizes up and a heart attack ensues.

The researchers suggest their findings show how diabetes can have this effect.

They compared samples of heart tissue taken from patients with and without diabetes who underwent heart transplants. The samples from patients with diabetes showed that their hearts had significantly fewer small blood vessels around them.

After running tests in the laboratory, the team also found high levels of blood sugar are linked to loss of pericytes - a type of cell that forms a protective layer around small blood vessels.

The team believes this layer stabilizes the blood vessel and causes the blood vessels to break up when damaged.

The researchers also studied the effect of blood vessel loss in pigs genetically engineered to develop type 1 diabetes that is like the human form. They found the same damage occurred in their hearts.

However, with the help of gene therapy, the team was able to increase production of a protein that stimulates growth of pericytes. This led to new growth of lasting and functioning small blood vessels.

It will be some time before such a treatment is available for use in humans, note the researchers, who also point out how the findings reinforce the importance of diagnosing diabetes early.

One in four people with diabetes do not know they have the disease. First author Dr. Rabea Hinkel, a cardiologist at TUM's university hospital, concludes:

"Diabetes often remains undetected in patients for years or even decades. Over that long period, massive damage can occur."

Learn how taking statins is linked to higher risk of diabetes in older women.

Read the rest here:
Diabetes: Heart attack risk due to loss of small blood vessels around the heart - Medical News Today

Posted in Diabetes | Comments Off on Diabetes: Heart attack risk due to loss of small blood vessels around the heart – Medical News Today

Learn how to fight diabetes and obesity in Pomona Saturday – Inland Valley Daily Bulletin

Posted: March 24, 2017 at 3:41 pm

POMONA >> Healthy eating and healthy living in Pomona will be topics of a forum taking place Saturday morning at Western University of Health Sciences.

The program, organized by Pomonas Health Promoters, will include topics such as diabetes prevention, obesity and the effects of drinking beverages with high sugar content, said Alejandra Martinez, program director of Pomonas Health Promoters.

Pomonas Health Promoters is a group of volunteers who have trained to assist fellow Pomona residents with a variety of issues, particularly health questions.

There are people in the community who are worried about diabetes, Martinez said. But we should be talking about the prevention of diabetes.

Promoters have brought together a group that includes health care professionals, representatives of health policy groups and others to talk about steps to a healthier life. Among the participants are representatives of the Universitys Western Diabetes Institute, City of Hope, Day One and Mt. San Antonio College.

Promoters have heard people talk about exercise and safety. People are interested in getting out of their houses, being more active and engaging in physical activity at local parks, Martinez said.

Some people say, Were going to go the park, but we dont feel safe there, she said. Local officials will be on hand Saturday to hear such concerns.

One of the panelists participating in the program will be Alfredo Camacho-Gonzalez, a healthy communities initiative project coordinator with Day One. The nonprofit works on quality, culturally sensitive public health education, intervention and policy development, according to the organizations website. Specifically, it seeks to increase access to healthy foods, make it easier for people to exercise and offer nutrition education, he said.

Such work is positive but cant end there, he said.

We back it up with policy change, Camacho-Gonzalez said.

The more people take part in activities that are healthy, the more it leads to policy that supports and continues to foster healthy behavior, he said.

Were trying to make healthy behavior the norm through policies and environmental changes, he said.

Pomona is a city where many people grow fruits and vegetables in their gardens, Martinez said. Rather than allowing the fruits and vegetables to go to waste, people can exchange produce, giving people greater access to healthy foods, she said.

Advertisement

Its about sharing ideas and creating new pathways to healthier eating practices, Martinez said.

Program registration begins at 8 a.m., with a healthy breakfast served at 8:30. The program will begin at 9 a.m. and conclude at noon.

Translation services will be available at the event.

The free event will take place at Western Universitys Veterinary Care Center, 611 E. Second St. Parking is available in Lot E on First and Palomares streets.

For information, call Martinez at 909-927-2345.

Follow this link:
Learn how to fight diabetes and obesity in Pomona Saturday - Inland Valley Daily Bulletin

Posted in Diabetes | Comments Off on Learn how to fight diabetes and obesity in Pomona Saturday – Inland Valley Daily Bulletin

HealthWatch: Diabetes Is A Growing Problem In Pets – CBS Chicago

Posted: March 24, 2017 at 3:41 pm

CHICAGO (CBS) On the health watch: Diabetes. It is a growing problem in our country, and you may be surprised to know your pet can suffer from diabetes just like you.

CBS 2s Roseanne Tellez has more on the growing incidence of diabetes in pets.

First a kiss, then a tiny pin prick in the ear a pet owner uses a meter specially calibrated for pets to test blood glucose levels.

Chelsea the cat was diagnosed with diabetes.

Cat owner, Eric Ravenstein was surprised to find out his cat, Chelsea, has diabetes.

We were a little shocked as well, and were a little scared because we did not know what it entailed, he said.

Dr. Ruth MacPete said Chelsea is one of a growing number of cats and dogs with diabetes.

Why the increase? Just like with humans, genetics, age and weight all play a role.

We are seeing much more obesity, not just with people, but with pets and with the rise in obesity were seeing an increase in diabetes, said Veterinarian, Dr. Ruth MacPete.

Left untreated, it can be dangerous.

It can lead to nerve damage, kidney disease and also death, Dr. MacPete said.

What are the signs? -increased thirst -increased urination including accidents in the house -increase in appetite even as they lose weight -lethargy

Dr. MacPete said the earlier the diagnosis, the easier it is to treat. Your veterinarian will give you instructions about giving insulin at home.

Diabetes is a manageable condition in dogs and cats just like it is in people, Dr. MacPete said. Pets can live a long happy healthy life. Chelsea is an example of that.

Diet is also very important keeping your pet trim and healthy. You will want to talk to your vet about that and all aspects of dealing with diabetes.

Here is the original post:
HealthWatch: Diabetes Is A Growing Problem In Pets - CBS Chicago

Posted in Diabetes | Comments Off on HealthWatch: Diabetes Is A Growing Problem In Pets – CBS Chicago

UPDATE: Lilly to invest $85M in Indy as part of diabetes expansion – Indianapolis Business Journal

Posted: March 24, 2017 at 3:41 pm

Citing a brisk demand for products and a full pipeline of potential new medicines, Eli Lilly and Co. plans to pour $850 million this year into its U.S. research labs, manufacturing plants and other operations, an increase of about $100 million from last year.

About $85 million of that will go to expand a manufacturing operation at the Lilly Technology Center southwest of downtown that assembles Trulicity injection pens for diabetes patients, the company said Friday.

Lilly CEO Dave Ricks said the total investment will fund projects that are already underway, as well as new projects.

As we have for our entire 140-year history, we continue to see Indiana and the United States as attractive places to research and make the medicines that we sell around the world, Ricks said.

The investment is the latest sign that Lilly, one of the largest employers in Indianapolis with about 11,500 jobs, remains bullish on its ability to roll out new products. In the past two years, the drugmaker has launched medicines for cancer, diabetes, psoriasis and other maladies. Company leaders have announced ambitious goals to launch 20 products in 10 years.

The company said the expanded Trulicity plant will be operating using current Lilly manufacturing employees, some of whom might come from elsewhere in the organization. Over the past five years, the company has added about 400 jobs in the city in U.S. diabetes manufacturing.

Ricks said Lilly plans to continue investing in its U.S. facilities, especially if the federal government adopts a more favorable tax environment. That would include lowering the U.S. corporate tax rate, adding certain innovation incentives, and an equitable treatment of foreign earnings, the company said.

Lilly had $28 billion of unremitted foreign earnings stashed overseas as of Dec. 31.

We consider these unremitted earnings to be indefinitely invested for continued use in our foreign operations, the company said in a footnote in its annual report. Additional tax provisions will be required if these earnings are repatriated in the future to the U.S.

Ricks made his comments at a press conference in front of the technology center, where a bright red banner draped across the building at least 30 feet high proclaimed Lilly invested in America.

For more than 140 years, Lilly has believed that investing in the U.S. and hiring U.S. workersincluding right here in our hometownmakes good business sense, Ricks said. Its no different now. What wed really love, however, is to do even more. And with a little help from Congress, I know we can.

Republicans in Congress have proposed a tax overhaul that would give companies more incentives to keep jobs in the United States, lowering the top corporate tax rate from 35 percent to 20 percent, and to stop taxing the income that U.S. companies make in other countries. The debate over the proposal is expected later this year.

Last year, Lilly paid $636.4 million in income taxes, at a tax rate of 18.9 percent, according to its annual report filed with the Securities and Exchange Commission. That was up from $381.6 million a year earlier, at a tax rate of 13.7 percent.

Ricks called the current corporate tax system antiquated, saying the U.S. is the only country that double-taxes the sales of products made here and exported to other countries. He said the system has encouraged companies to expand production overseas.

Mayor Joe Hogsett, a Democrat, applauded Lillys investment but, in an interview afterward, declined to say whether he shared Ricks support of Republican tax reform.

Im staying away from the Washington partisan divide, he said.

Gov. Eric Holcomb called Lillys investment the latest sign that Indianas low-tax, low-regulation business environment is working.

Companies like Eli Lilly can go anywhere in the world, he said. We are a low-tax state and we are benefiting from it.

Lillys expansion is part of a five-year, $1.1 billion investment to expand diabetes products manufacturing in the United States. The company announced in 2012 it would build a $140 million facility for insulin cartridge production in Indianapolis. A year later, it announced it would spend another $180 million to more than double the size of the facility.

More than 400 million people around the world have diabetes, including about 30 million Americans.

Continue reading here:
UPDATE: Lilly to invest $85M in Indy as part of diabetes expansion - Indianapolis Business Journal

Posted in Diabetes | Comments Off on UPDATE: Lilly to invest $85M in Indy as part of diabetes expansion – Indianapolis Business Journal

Lauren Cox juggles Type 1 diabetes in first season at Baylor – ESPN

Posted: March 24, 2017 at 3:41 pm

WACO, Texas -- Trying to please the demanding Kim Mulkey and adjusting from high school to elite college basketball at Baylor could lead to a breakdown for any freshman. But Lauren Cox's major freshman issue had nothing to do with any of that. Her misery before Baylor faced Tennessee on Dec. 4 was all because the biggest challenge of her life -- Type 1 diabetes -- threatened to keep her from playing in the game. Her blood sugar levels were dangerously high.

Cox ended up taking the floor in the Baylor win. Her blood sugar returned to the necessary level to allow her to play. Still, she admits it's been incredibly challenging -- dealing with her condition, working to succeed on the court for a top program and trying to be a freshman in college all at the same time.

"It's been pretty tough," Cox said this week, before Baylor faces Louisville in the Sweet 16 on Friday night (ESPN2/WatchESPN, 9 p.m. ET). "Not having my parents there (at Baylor) is definitely a big challenge. Just managing my levels has been pretty tough but I've had a pretty good handle on it."

As Louisville and Baylor prepare to clash again in the Sweet 16, you can't help but look back at the Cardinals' epic upset in 2013. So much has changed, but the Lady Bears remain the favorite.

Natalie Chou can't help the comparisons to Linsanity as she attempts to shatter stereotypes. From pro-style workouts with Jason Terry to navigating her first year at Baylor, this is her story.

1 Related

On the court, Cox has flashed the potential that made her the top recruit in the country. She has been a key reserve for Mulkey, earning the Big 12 Sixth Man Award while being named to the All-Freshman team after averaging 8.4 points, 4.5 rebounds and 1.6 blocks per game.

That is even more impressive considering Cox has to watch and count every carb she eats. The 6-foot-4 power forward, who has dealt with her condition since she was 7, pricks her finger up to 12 times a day to watch her blood sugar. She takes insulin before she eats and has to test her levels before, during and after practices and games. She will check her levels every hour in practice, with the Baylor trainers keeping an eye on her.

Otherwise, the consequences of playing with high blood sugar levels can be devastating.

"It is really bad on my body," Cox said. "In the long term, I can lose limbs, lose my eyesight -- that kind of stuff; if it gets really bad, it can take years off of my life, and I have to make sure I have a good handle on it."

That is why Mulkey vowed to Cox's parents that she wouldn't play their daughter with high blood sugar and risk her health. Before that Tennessee game, Mulkey was prepared not to play Cox in Baylor's first game on ESPN2 this season.

"Initially when I found out that it was too high, she was a basket case," Mulkey said. "She had a meltdown and wanted to play and I had to be stern with her and tell her, 'While you may have played like this throughout your career, I made a commitment to your parents that your health is most important. And you are not going to play until [your numbers] get to a reasonable level.'"

Cox played a total of seven minutes while battling foul trouble in Baylor's 88-66 win over Tennessee.

"I can get really frustrated just with myself, and it is really hard not being able to play and not being able to contribute," Cox said. "And if my team needs me, just not being able to be out there."

So far in her first NCAA tournament, Cox has posted a total of 24 points, 10 rebounds, 5 assists, 3 steals and 3 blocks in 41 combined minutes through Baylor's first two wins.

Entering the season, Cox said she hoped to use the visibility that comes with playing for a premier women's program such as Baylor to help educate and inspire others who live with Type 1 diabetes.

Baylor hosted a Type 1 Diabetes Awareness Night earlier this season, and Cox hopes to be a role model as her career goes on in college and beyond.

"That's a big thing," Cox said. "I feel like doctors may say, 'Oh, you have to cut down on this sport' or something like that -- 'just because you have diabetes.' I just want to show them that you can do anything that you set your mind to."

Mulkey has had to learn how to handle her coveted freshman's emotions when it comes to dealing with daily ups and downs that can come with Type 1 diabetes.

"I realize she is tender when it comes to her diabetes and yet she is tough because it is something she has had to cope with since she was 7 years old," Mulkey said. "It has not affected her ability; it has not affected how great of a player she is and will continue to be.

"It's kind of, in her words, a nuisance. It's our job as leaders of this program to make sure that she understands: Your health and safety come first, and make sure your levels are where they are supposed to be when you play."

View original post here:
Lauren Cox juggles Type 1 diabetes in first season at Baylor - ESPN

Posted in Diabetes | Comments Off on Lauren Cox juggles Type 1 diabetes in first season at Baylor – ESPN

The Equities Research Analysts’ Updated EPS Estimates for March, 20th (AIMT, AMID, AUPH, AVD, BDREF, BPTH … – Petro Global News 24

Posted: March 23, 2017 at 4:43 am

Equities Research Analysts updated eps estimates for Monday, March 20th:

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Companys characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.

American Midstream Partners (NYSE:AMID) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, American Midstream Partners, LP owns, operates, develops and acquire a diversified portfolio of natural gas midstream energy assets. The Company is engaged in the business of gathering, treating, processing and transporting natural gas through its ownership and operation of gathering systems, processing facilities and pipelines. Its primary assets, which are located in Alabama, Louisiana, Mississippi, Tennessee and Texas, provide infrastructure that links producers and suppliers of natural gas to diverse natural gas markets, including various pipelines, as well as utility, industrial and other commercial customers. American Midstream Partners, LP is based in Denver, Colorado.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The companys lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

American Vanguard Corp. (NYSE:AVD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, AMERICAN VANGUARD CORP. is a holding company, which through its subsidiaries, is engaged in the manufacturer and formulation of chemicals for crops, human and animal health protection. These chemicals which include insecticides, fungicides, molluscicides, growth regulatorsain, and soil fumigants, are marketed in liquid, powder, and granular forms.

Beadell Resources (NASDAQ:BDREF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Beadell Resources Limited is a gold producer. It owns and operates the Tucano gold mine primarily in Brazil. Beadell Resources Limited is based in West Perth, Australia.

Bio-Path Holdings (NASDAQ:BPTH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $0.75 target price on the stock. According to Zacks, BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Paths drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.

COBHAM (NASDAQ:CBHMY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Cobham Plc is engaged in designing and manufacturing equipment as well as components for defence and security, aerospace, space, marine and electronic industries. It primarily operates through segments which include Communications and Connectivity, Advanced Electronic Solutions, Mission Systems and Aviation Services. The Communications and Connectivity segment provides communication equipment, law enforcement and national security solutions and satellite communication equipment for land, sea and air applications. The Advanced Electronic Solutions segment provides technology and solutions for intelligence operations and systems to communicate on land, sea and air. The Mission Systems segment provides safety and survival systems for environments, weapons carriage and equipment for fast jets, transport aircraft, rotor craft, remote controlled robots and bomb disposal vehicles for military application. The Aviation Services segment provides outsourced aviation services for military and civil customers as well as

CBL & Associates Properties (NYSE:CBL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, CBL & Associates Properties, Inc. is a fully integrated real estate investment trust which owns, develops, acquires, leases, manages, and operates regional shopping malls, open-air centers, community centers and office properties. The Company conducts substantially all of its business through its operating partnership. It owns two qualified REIT subsidiaries: CBL Holdings I, Inc. and CBL Holdings II, Inc. CBL & Associates Properties is headquartered in Chattanooga, Tennessee.

Carnival Corp (NYSE:CCL) was upgraded by analysts at William Blair from a market perform rating to an outperform rating.

China Unicom (Hong Kong) Limited (NYSE:CHU) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a buy rating. The firm currently has $15.00 price target on the stock. According to Zacks, China Unicom Limited is engaged in the provision of cellular, paging, long distance, data and internet services in the Peoples Repulic of China.

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.

Carrefour Sa Spon (NASDAQ:CRRFY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, Carrefour S.A. operates hypermarkets, supermarkets, convenience stores and cash and carry stores in Europe, the Americas and Asia. Carrefour S.A. is headquartered in Boulogne-Billancourt, France.

Cytori Therapeutics (NASDAQ:CYTX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Companys preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patients own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Countrywide (NASDAQ:CYWDF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Countrywide plc provides property services which includes estate agency and lettings network. The companys business unit consists of Retail, London, B2B and Financial Services. Countrywide plc is headquartered in Milton Keynes, the United Kingdom.

Tableau Software (NYSE:DATA) had its buy rating reiterated by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $70.00 price target on the stock.

Evoke Pharma (NASDAQ:EVOK) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Companys lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.

POWERSHARES GLBAL FUNDS IRELAND PLC POWERSHARES EQQQ NASDAQ-100 UCITS ETF (NASDAQ:IRELAND) was upgraded by analysts at Wells Fargo & Co from a market perform rating to an outperform rating.

JPMorgan Chase & Co. (NYSE:JPM) had its overweight rating reaffirmed by analysts at Barclays PLC. The firm currently has a $100.00 target price on the stock.

Starbucks (NASDAQ:SBUX) had its outperform rating reiterated by analysts at Wells Fargo & Co. Wells Fargo & Co currently has a $65.00 target price on the stock.

Steel Dynamics (NASDAQ:STLD) had its neutral rating reiterated by analysts at Macquarie.

See the original post:
The Equities Research Analysts' Updated EPS Estimates for March, 20th (AIMT, AMID, AUPH, AVD, BDREF, BPTH ... - Petro Global News 24

Posted in Alabama Stem Cells | Comments Off on The Equities Research Analysts’ Updated EPS Estimates for March, 20th (AIMT, AMID, AUPH, AVD, BDREF, BPTH … – Petro Global News 24

BIO Announces Plenary Sessions for 2017 World Congress on … – Business Wire (press release)

Posted: March 23, 2017 at 4:42 am

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today released the list of speakers for plenary programs at the2017 World Congress on Industrial Biotechnology. The sessions will feature executives from the biofuels, household and personal care, and airline industries who will discuss technology breakthroughs, business partnerships and sustainability initiatives. The worlds largest industrial biotechnology event will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Qubec, Canada.

Brent Erickson, Executive Vice President, Industrial and Environmental at BIO, stated, The Plenary Program for the 2017 World Congress will cover several novel topics that are emerging within the industry. Panelists will provide an overview of the current state of biobased food ingredients, flavorings, and personal care products and where market trends are headed in the future. Additionally, industry representatives and trade reporters will discuss how to meaningfully communicate about the biobased economy.

Some highlighted Plenary Sessions include:

Biotech and the Future of Food Ingredients, Flavorings, and Personal Care Monday, July 24, 2017 3:45 pm - 5:00pm

Speakers:

Second Generation Biofuels Poised for Big Wins Tuesday, July 25, 2017 8:30 am - 10:00am

Moderator:Jim Lane, Editor and Publisher, The Digest Speakers:

Effectively Communicating the Benefits of Industrial Biotechnology Tuesday, July 25, 2017 11:45 am 1:30 pm

Moderator:Rebecca Coons, Senior Editor, Chemical Week, IHS Chemical Speakers:

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentarymedia registrationis available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference please visithttp://www.bio.org/worldcongress. For assistance, please contactworldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces theBIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOWis BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO-Europe Spring Conference March 20-22, 2017 Barcelona, Spain

BIO IP Counsels Committee Conference March 27-29, 2017 Newport Beach, CA

BIO International Convention June 19-22, 2017 San Diego, CA

BIO World Congress on Industrial Biotechnology July 23 - 26, 2017 Montral, Canada

Read the original post:
BIO Announces Plenary Sessions for 2017 World Congress on ... - Business Wire (press release)

Posted in Biotechnology | Comments Off on BIO Announces Plenary Sessions for 2017 World Congress on … – Business Wire (press release)

Lookout for Price Target? EP Energy Corporation (EPE), Puma … – StockNewsJournal

Posted: March 23, 2017 at 4:42 am


StockNewsJournal

See the rest here:
Lookout for Price Target? EP Energy Corporation (EPE), Puma ... - StockNewsJournal

Posted in Biotechnology | Comments Off on Lookout for Price Target? EP Energy Corporation (EPE), Puma … – StockNewsJournal

Plasma and stem cells: The future of regenerative medicine | WEAR – WEAR

Posted: March 23, 2017 at 4:42 am

Plasma and stem cells: The future of regenerative medicine

Blood platelet injections and stem cell treatments may sound like the future, but physicians at the Andrews Institute are already practicing these forms of regenerative medicine.

Weight lifting mixed with normal wear and tear left Howie Webber in constant pain.

"I probably felt it about four months ago," said Howie. "I did some stretching, thinking I could make it go away, but it just continued to get worse."

That's when Howie went to the doctor and found out he had two options: surgery or regenerative medicine; he picked the latter.

"I just added up the amount of time I'd be out of work and the cost of surgery, plus the copay and this whole thing just seemed like it would be a little faster and a little easier, and it ended up being just that," said Howie.

Physicians at the Andrew's Institute currently offer two different types of regenerative medicine, platelet rich plasma, or PRP and bone marrow aspirate concentrate, or BMAC.

With PRP, physicians take the patient's blood, separate the platelets and inject those platelets back into the patient at the site of injury. The idea is that platelets carry growth factors and molecules to stimulate the healing process.

BMAC utilizes platelets too, but also the patient's bone marrow harvested from the pelvis.

Both regenerative medicine methods have benefits, perhaps the biggest according to Dr. Brett Kindle, is avoiding invasive surgeries.

"If we need surgery, we need surgery, and that's what it is, but if we can avoid it, that often times is very beneficial from a financial standpoint, missing less work, etc.," said Dr. Kindle. "Also from a quality of life, to be able to get back to doing activities in a more timely manner."

The main difference between the two is price and neither are covered by insurance. BMAC costs upwards of $3,000, while PRP costs anywhere from $600 to $800. Howie opted for PRP.

"It hurt for about three days, then within a week I was pain free," said Howie. "Maybe a little discomfort that you would expect, but it wasn't near as bad as it was before."

Howie's issue was with his hamstrings, but Dr. Kindle said both PRP and BMAC can be used to treat a variety of aches and pains.

"Anything in the limbs," said Dr. Kindle. "Shoulders, elbows, hands, wrists, hips, knees, foot, ankle, all of those areas."

Recovery for both PRP and BMAC procedures is typically one to two weeks. Full effects of the injections don't usually kick in until six to eight weeks later. For more information about regenerative medicine or to schedule a consultation with an Andrews Institute physician, call (850) 916-8700.

Continued here:
Plasma and stem cells: The future of regenerative medicine | WEAR - WEAR

Posted in Cell Medicine | Comments Off on Plasma and stem cells: The future of regenerative medicine | WEAR – WEAR

Three-pronged approach is key to precision medicine – Cornell Chronicle

Posted: March 23, 2017 at 4:42 am

Combining genetic information from a patients tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed, according to a new study led by Weill Cornell Medicine investigators.

Published March 22 in Cancer Discovery, the study brings researchers one step closer to fulfilling the promise of precision medicine, which aims to provide targeted, individualized treatment based on each patients genetic profile.

Our goal is to use precision medicine to improve the way clinicians think about cancer therapies as opposed to selecting a therapy that may not be fitted to that patients cancer, said senior author Dr. Mark Rubin, director of the Englander Institute for Precision Medicine and the Homer T. Hirst III Professor of Oncology in Pathology at Weill Cornell Medicine, and director of the joint precision medicine program at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. Combining genome sequencing with rapid drug screening enables us to nominate new therapies for patients, which we could not have predicted from the genomics alone.

Cancer genetics research has made great strides in the last 20 years, allowing investigators to now identify mutations in tumor cells that are susceptible to treatment. Still, a significant number of cases remain in which genetic mutations cannot indicate to clinicians exactly what drug will be effective in treating a patients disease, particularly for those with advanced cancers that have failed multiple therapies.

To better treat these patients, Rubin and the research team including co-first authors Dr. Chantal Pauli, a former research fellow in Rubins lab, and Benjamin Hopkins, a postdoctoral associate in co-author Dr. Lewis C. Cantleys lab developed an approach in which tumor cells taken from patients are grown into three-dimensional cell cultures called tumor-derived organoids. The researchers can then test more than 120 U.S. Food and Drug Administration-approved cancer drugs against the organoids to determine which drugs show the most promise. After identifying a potential treatment, they transplant the organoid into a mouse to assess how well the tumor responds to the drug. The organoid cell culture system, Rubin said, markedly accelerates the identification of potential therapies compared with current approaches, which depend on growing tumor cells in mice.

With the organoid system, we can obtain answers in one to two months, compared to six months to a year with mice, Rubin said. This is critically important for patients with advanced cancer. We need to strive to identify new and more effective therapies in a timely manner.

Dramatic improvements in the ability to grow tumors as organoids outside the body is bringing precision medicine to the next level of precision, added Cantley, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. It is now possible to grow a wide variety of tumors outside of the body; this allows the precision medicine team to not only obtain full exome and RNA sequencing data, but also test a panel of approved drugs on the same tumor that is growing in the patient. Importantly, this can occur within a time scale that would allow one to make a clinical decision about the next therapy, should the tumor progress on standard of care.

This approach could revolutionize how cancers are treated in the future, he said, by providing oncologists with detailed information about the genetic aberrations, the gene expression profiles and the response to drugs of the same tumor that is growing in the patient.

For the study, researchers analyzed tumor-derived cells from four patients who came to the Englander Institute for care. Two of the patients had different forms of uterine cancer, while the other two had different forms of colon cancer. The scientists identified effective drugs and drug combinations many of which are medications approved for treating other cancers that they subsequently validated using organoid cultures and organoids transplanted into mice.

Specifically, the researchers discovered that the combination of two breast cancer drugs could treat one of the uterine cancer cases. For the other, one of the top treatments was a combination of a breast cancer drug and a lymphoma drug.

The investigators found that a colon cancer drug combined with one approved for metastatic melanoma could treat one of the colon cancer cases; they believe their results could establish a basis for a clinical trial. For the other colon cancer case, the scientists identified a therapy that combines a lung cancer drug with one approved for treating blood cancers such as lymphoma and multiple myeloma.

At the moment, there is no standard to guide a clinicians decision of when to give a patient a drug thats not recommended by the FDA, Rubin said. With this study, were trying to establish a standard that uses a patients cells to answer that question.

This study was supported in part by the National Institutes of Health, the Starr Cancer Consortium and the Prostate Cancer Foundation.

Joseph Bonner is a freelance writer for Weill Cornell Medicine.

Excerpt from:
Three-pronged approach is key to precision medicine - Cornell Chronicle

Posted in Cell Medicine | Comments Off on Three-pronged approach is key to precision medicine – Cornell Chronicle